These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22407977)

  • 1. Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.
    Canziani GA; Melero JA; Lacy ER
    J Mol Recognit; 2012 Mar; 25(3):136-46. PubMed ID: 22407977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
    McGivney JB; Bishop E; Miller K; Casas-Finet J; Yang H; Wei Z; Strouse R; Schenerman M
    J Pharm Biomed Anal; 2011 Feb; 54(3):572-6. PubMed ID: 20943340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning.
    Tsui P; Tornetta MA; Ames RS; Bankosky BC; Griego S; Silverman C; Porter T; Moore G; Sweet RW
    J Immunol; 1996 Jul; 157(2):772-80. PubMed ID: 8752928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans.
    Fuentes S; Hahn M; Chilcote K; Chemaly RF; Shah DP; Ye X; Avadhanula V; Piedra PA; Golding H; Khurana S
    J Infect Dis; 2020 Feb; 221(4):636-646. PubMed ID: 31745552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
    J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.
    McLellan JS; Chen M; Chang JS; Yang Y; Kim A; Graham BS; Kwong PD
    J Virol; 2010 Dec; 84(23):12236-44. PubMed ID: 20881049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies Against the Human Respiratory Syncytial Virus Obtained by Immunization with Epitope Peptides and CpG-DNA-liposome Complex.
    Park BK; Choi SH; Kim YE; Park S; Lee Y; Lee KW; Kwon HJ
    Monoclon Antib Immunodiagn Immunother; 2015 Apr; 34(2):101-9. PubMed ID: 25897608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Fab display and selection through fusion to the pIX coat protein of filamentous phage.
    Tornetta M; Baker S; Whitaker B; Lu J; Chen Q; Pisors E; Shi L; Luo J; Sweet R; Tsui P
    J Immunol Methods; 2010 Aug; 360(1-2):39-46. PubMed ID: 20600082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.
    Xie Q; Wang Z; Ni F; Chen X; Ma J; Patel N; Lu H; Liu Y; Tian JH; Flyer D; Massare MJ; Ellingsworth L; Glenn G; Smith G; Wang Q
    PLoS One; 2019; 14(2):e0210749. PubMed ID: 30730999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction and preliminary panning of Fab phage display antibody library against respiratory syncytial virus].
    Wang ZH; Zhang GC; Li AM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Dec; 10(6):681-5. PubMed ID: 19102829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.
    Fuentes S; Coyle EM; Beeler J; Golding H; Khurana S
    PLoS Pathog; 2016 Apr; 12(4):e1005554. PubMed ID: 27100289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
    Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
    J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.
    Rossey I; Gilman MS; Kabeche SC; Sedeyn K; Wrapp D; Kanekiyo M; Chen M; Mas V; Spitaels J; Melero JA; Graham BS; Schepens B; McLellan JS; Saelens X
    Nat Commun; 2017 Feb; 8():14158. PubMed ID: 28194013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.